1 June 2017 in Turkish Journal of Ophthalmology
Diabetic macular edema is the most common cause of visual impairment in patients with diabetes mellitus. The pathogenesis of macular edema is complex and multifactorial. For many years, laser photocoagulation has been considered the standard therapy for the treatment of diabetic macular edema; however, few patients achieve significant improvements in visual acuity. Today the intravitreal administration of anti-inflammatory or anti-angiogenic agents together with the use of laser photocoagulation represents the standard of care for the treatment of this complication. The intravitreal route of administration minimizes the systemic side effects of corticosteroids. Steroid-related ocular side effects are elevated intraocular pressure and cataract, while injection-related complications include endophthalmitis, vitreous hemorrhage, and retinal detachment. In order to reduce the risks and complications, intravitreal implants have been developed recently to provide sustained release of corticosteroids and reduce repeated injections for the management of diabetic macular edema. In this review, the efficacy, safety, and therapeutic potential of intravitreal corticosteroids in diabetic macular edema are discussed with a review of recent literature.
27 June 2021 in International Ophthalmology
13 February 2024 in International Ophthalmology
30 September 2017 in International Journal of Ophthalmology and Clinical Research
The aim of this study is to ascertain whether diabetes mellitus (DM) affects the macular GCIPL thickness in patients who have Nonproliferative Diabetic Retinopathy (NPDR) or no DR using Cirrus HD-OCT and to consider the relationship between GCIPL measurements and age, sex, duration of diabetes, DR status, glycated hemoglobin (HbA1c) level, Hypertension (HT) duration, and hypertensive retinopathy status.
6 April 2026 in Clinical and Experimental Optometry
Blue-violet light-filtering daily contact lenses are becoming more popular as a way of addressing the visual challenges associated with prolonged exposure to digital screens and low-light environments. Optimising contrast sensitivity in such situations is important for visual comfort, functional performance and patient satisfaction, especially among individuals with high visual demands or frequent exposure to glare. Digital device use has increased exposure to short-wavelength light, contributing to visual fatigue and reduced contrast sensitivity. Blue-violet - filtering soft contact lenses have been developed to enhance visual performance; however, independent clinical data comparing such lenses to non-filtering designs manufactured from the same material remain limited. This retrospective comparative study analysed 45 myopic adults fitted with two senofilcon-A daily disposable lenses: OASYS (non-filtering) and MAX (blue-violet filtering). Contrast sensitivity (photopic, mesopic, glare), corneal aberrations, and non-invasive tear break-up time (NIBUT) were assessed. Repeated-measures ANOVA and regression analyses were used to evaluate lens-related differences and identify predictors of contrast sensitivity. MAX lenses demonstrated significantly higher contrast sensitivity at medium-to-high spatial frequencies under photopic and mesopic conditions, and at low-to-mid frequencies with glare. Tear-film stability was preserved with both lenses without clinically meaningful differences. Corneal aberration changes were small; higher coma and trefoil values correlated with reduced contrast sensitivity during MAX wear. No demographic or pupil-related factors influenced outcomes. Blue-violet - filtering MAX lenses provide measurable improvements in contrast sensitivity, particularly under low light and glare. While tear-film stability remained comparable between lenses, optical design features of the MAX lens contributed to enhanced visual performance. These findings support their use in patients with high digital-screen exposure or night-time visual demands.
29 August 2026 in International Ophthalmology